摘要:
A rolling-ball switch includes a casing having two racks. A chamber is defined after a round stage and a sealing groove are fit in the casing. The chamber includes a first contact plate, a second contact plate and a third contact plate on two ends faces thereof and forming a switch with a conductive ball. The third contact plate is connected integrally with a common terminal and an open groove is defined between the first contact plate and the second contact plate. The first contact plate and the second contact plate are connected to a first terminal and a second terminal outside a casing. The switch is rotated to turn off power when an electrical device is rotated more than a predetermined angle. The predetermined angle can be adjusted by setting an angle between the open groove and a vertical line.
摘要:
A pharmaceutical composition comprises a drug-carrier system having a small-molecule drug of low water solubility, e.g. N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), and (+)-1-(5-tert-butyl-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102), in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The drug-carrier system, when mixed with an aqueous phase, typically forms a non-gelling, substantially non-transparent liquid dispersion. The composition is suitable for administration by a suitable route, e.g. orally, to a subject in need thereof.
摘要:
A semiconductor diode laser system with microwave mode locking. The system includes a semiconductor laser diode and an external reflector positioned to receive radiation that emits from the diode and reflects the same back into the diode, the microwave mode locking serving to modulate the radiation and the external reflector being properly positioned to return the radiation to the diode at a return time equal to the period of the drive signal or a submultiple thereof.
摘要:
An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
摘要:
An optical apparatus for measuring the velocity of flowing biomaterials is disclosed, which has a coherent light source for projecting a light beam with low coherent length; a reference member having mirrors for periodically reflecting lights thereon; a photo detector for receiving photo signals; a splitter for splitting said light beam from said coherent light source into a reference beam and a detecting beam. The disclosed optical apparatus can save the time for complicate computation and the cost of software or hardware for measuring the flowing velocity of biomaterials, especially the flowing velocity of flowing bloods in vessels.
摘要:
Real-time clinical diagnostic expert systems for fluorescent spectrum analysis of tissue cells and methods thereof. An exemplary system includes a set of optical fibers, wherein the first optical fiber introduces an incident light to an subject epidermal tissue, and the second optical fiber receives an auto-fluorescent signal, a set of monochromators, wherein the first monochromator produces the incident light, and the second monochromator produces the auto-fluorescent signal from the second optical fiber, a light detector for detecting the auto-fluorescent signal from the second monochromator, a signal processing unit for plotting a spectrum of the auto-fluorescent signal, and a spectrum analyzing unit comprising a database for analyzing the spectrum with the database to obtain a probability of disease for the subject epidermal tissue.
摘要:
A manufacturing process is provided for fabrication of vertically coupled integrated photonic devices by projection lithographic technique. A multi-layered structure is formed which includes a pair of core waveguiding layers separated by a coupling interlayer and sandwiched between cladding layers. Prior to forming optical features in the core layers, alignment marks are etched completely through the whole multi-layered structure with the alignment marks being visible on both sides of the multi-layered structure to a conventional projection stepper. After the alignment marks are formed, a “bottom level” optical features are made through the bottom cladding layer, bottom core layer, and portion of intervening coupling layer. The formed sample is then bonded by a polymer to a carrier and a “top level” optical features are defined through the top cladding, top core layer, and portion of the intervening coupling layer.
摘要:
A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
摘要:
A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
摘要:
An orally deliverable pharmaceutical composition comprises (a) a pharmaceutically acceptable acid addition salt of ABT-263 in solid particulate form, and (b) a plurality of pharmaceutically acceptable excipients including at least a solid diluent and a solid disintegrant; wherein the salt is formed from more than one equivalent of acid per equivalent of ABT-263. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.